Page 2 - Garya Lyons News Today

Cantor Fitzgerald reissued their overweight rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research note published on Wednesday, Benzinga reports. The firm currently has a $136.00 price target on the stock. NBIX has been the subject of several other research reports. Stifel Nicolaus cut their price target on Neurocrine Biosciences from […]

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As discussed... | May 19, 2023

New York State Teachers Retirement System cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 2.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 58,774 shares of the company’s stock after selling 1,275 shares during the period. New York State Teachers Retirement System’s holdings […]

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 3,580,000 shares, a decrease of 17.1% from the May 15th total of 4,320,000 shares. Currently, 3.8% of the shares of the stock are short sold. Based on […]

Equities analysts forecast that Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) will post earnings per share (EPS) of $0.49 for the current fiscal quarter, Zacks Investment Research reports. Eleven analysts have provided estimates for Neurocrine Biosciences’ earnings. The lowest EPS estimate is $0.31 and the highest is $0.75. Neurocrine Biosciences reported earnings per share of […]

Community notices